ADO and COVID-19: In order to investigate whether lower availability of ADO could contribute to the pro-inflammatory profile of COVID-19, MNCs from patients with severe COVID-19 and HDs were cultured with a TLR7/TLR8 agonist (CL097, imidazoquinoline-derived compound) under the presence or absence of ADO.